Adding Citius (CTXR) $0.55 to Watch List.
Disclaimer. Citius Pharma is a client, please see reports for disclosure and disclaimer details.
- Biotech News
- 2020 Watch List
- 2021 Watch List
- All News
- Client
- CoronaVirus
- Incubator
- Infections
- Institutional Analyst Newsletter
- Interview
- Stem Cells
Interview: Citius Pharma (CTXR) $1.74, Chairman Leonard Mazur.
Latest article
Inbcubator Society Pass (SOPA), Expanding into Private AI Software Companies, and Private AI Data...
Society Pass was riding high earlier this year, after announcing they successfully spun off one of its holding companies, into a publicly traded entity,...
GeoVax (GOVX) Reports Both Favorable Safety and “It’s Working” News for its Cancer...
Official Headline is "GeoVax Announces JCO Oncology Advances Publication Highlighting Favorable Safety and Evidence of Disease Stability of Gedeptin(R) in Recurrent Head & Neck...
Biotech Stock Review. All Ideas, 2020-2025.
Top Ideas as Defined by 'Peak Gain' from 2020 to 2025
This is every stock we've covered and added to the Watch List during that...
